Spectrum's Pivotal BELIEF: PTCL Data 'Topo' the Mark
By Randy Osborne
Friday, December 21, 2012
Spectrum Pharmaceuticals Inc.'s endpoint-beating success in the pivotal Phase II study with belinostat for relapsed/refractory peripheral T-cell lymphoma keeps the firm on track potentially to pair the pan-histone deacetylase inhibitor with Spectrum's antifolate Folotyn, already approved for the condition.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.